Cargando…

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma

The objective of this study was to evaluate the feasibility of developing personalized, tumor-informed assays for patients with high-risk resectable melanoma and examine circulating tumor DNA (ctDNA) levels in relation to clinical status. Pilot prospective study of clinical stage IIB/C and resectabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunsgaard, Elise K., Bowles, Tawnya L., Asare, Elliot A., Grossmann, Kenneth, Boucher, Kenneth M., Grossmann, Allie, Jackson, Julie A., Wada, David A., Rathore, Richa, Budde, Griffin, Grandemange, Andrew, Hyngstrom, John R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144272/ https://www.ncbi.nlm.nih.gov/pubmed/37040662 http://dx.doi.org/10.1097/CMR.0000000000000892

Ejemplares similares

Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature
por: Bleicher, Josh, et al.
Publicado: (2021)

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
por: Ray, Abhijit, et al.
Publicado: (2016)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Effects of adiponectin on breast cancer cell growth and signaling
por: Grossmann, M E, et al.
Publicado: (2008)

Malignant melanoma scrotal metastasis: The importance of the genital examination
por: Gonzalez, Cristian D., et al.
Publicado: (2016)

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
por: Slingluff, Craig L, et al.
Publicado: (2021)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
por: Zakharia, Yousef, et al.
Publicado: (2021)

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
por: Carpenter, Elizabeth Lee, et al.
Publicado: (2023)

Impact of rurality on melanoma diagnosis in Utah
por: Bowles, Tawnya L, et al.
Publicado: (2021)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

The influence of paediatric HIV infection on circulating B cell subsets and CXCR5(+) T helper cells
por: Bamford, A., et al.
Publicado: (2015)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

Detection of Exosomal miRNAs in the Plasma of Melanoma Patients
por: Pfeffer, Susan R., et al.
Publicado: (2015)

Melanoma: What Are the Gaps in Our Knowledge?
por: Rees, Jonathan L
Publicado: (2008)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Classification, Molecular Characterization, and the Significance of Pten Alteration in Leiomyosarcoma
por: Grossmann, Allie H., et al.
Publicado: (2012)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Increased expression of class III β-tubulin in castration-resistant human prostate cancer
por: Terry, S, et al.
Publicado: (2009)

Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid
por: Lok, Edwin, et al.
Publicado: (2014)

Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model
por: Thies, A, et al.
Publicado: (2008)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
por: Thies, A, et al.
Publicado: (2007)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

Elastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase
por: Devy, J, et al.
Publicado: (2010)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2017)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
por: Abecunas, Cara, et al.
Publicado: (2023)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Micro-Organisms in Dental Caries
por: Goadby, Kenneth W.
Publicado: (1900)

The Discoloration of Copper Amalgam
por: Goadby, Kenneth W.
Publicado: (1897)

Cannot write session to /tmp/vufind_sessions/sess_bck6qe7ufvvkgivjr43c0in2r4